Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease.
BACKGROUND
The use of calcitriol in the treatment of uremic hyperparathyroidism and renal osteodystrophy is limited in many patients by hypercalcemic side-effects. New less calcemic analogues of calcitriol are being developed, and some are under clinical evaluation. To investigate whether these compounds possess important differences in their action on bone cells, we have studied their effects [with and without parathyroid hormone (PTH)] on the release and synthesis of the resorptive osteotropic cytokine, interleukin-6 (IL-6).


METHODS
MG 63 and SaOS-2 human osteoblastic cell lines were cultured for 6 or 24 hours in media containing calcitriol, the sterols of interest, or 1-34 synthetic PTH. IL-6 release was assayed by commercially available enzyme-linked immunosorbent assay. IL-6 mRNA levels were assessed by reverse transcriptase-polymerase chain reaction.


RESULTS
We found that calcitriol and paricalcitol behaved in a similar fashion, resulting in increased IL-6 release only at higher concentrations (10(-7) to 10(-9) M). In contrast, 22-oxacalcitriol and 1,25-dihydroxydihydrotachysterol2 stimulated release to a similar extent but at concentrations three to four orders of magnitude lower (10(-11) to 10(-13) M), despite being less potent as suppressers of parathyroid function than calcitriol. Studies of IL-6 mRNA showed a similar pattern of concentration and cell line-dependent transcription.


CONCLUSIONS
Compounds stimulating IL-6 release at concentrations achievable during the treatment of uremic hyperparathyroidism might favor continuing linked bone formation and resorption and thereby avoid adynamic bone disease while still allowing profound suppression of PTH.
McIntyre
C W
CW
Department of Renal Medicine and Transplantation, Royal London Hospital, United Kingdom.
Schroeder
N J
NJ
Burrin
J M
JM
Cunningham
J
J
D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology; D002117:Calcitriol / Q000031:analogs & derivatives / Q000494:pharmacology; D002460:Cell Line; D004097:Dihydrotachysterol / Q000031:analogs & derivatives / Q000494:pharmacology; D004872:Ergocalciferols / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D014511:Uremia / Q000150:complications; D014807:Vitamin D / Q000031:analogs & derivatives*